Published in Gene Therapy Weekly, February 10th, 2000
"Expression of B7 on tumor cells can circumvent T-cell tolerance and lead to the generation of tumor cell specific T-cell immunity," wrote P. T. Daniel and colleagues from Humboldt University and Theragen AG, Germany. "Therefore, gene modified tumor cells with vectors for the expression of B7 have been extensively studied in experimental tumor cell vaccination."
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.